Vyriad
PrivateLast Round
Series B
Dec 23, 2025
Total Funding Raised
$150.38M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Vyriad is a biotechnology company that develops targeted genetic therapies using engineered viruses, viral vectors, and viral envelope glycoproteins for oncolytic virotherapy, in vivo gene therapy, and gene editing applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vyriad Comparables
Compare Vyriad with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ensoma | 82% | |
| AbbVie | 81% | |
| Eli Lilly and Company | 81% | |
Vyriad Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 23, 2025 | ||||
| Series B | May 17, 2022 | ||||
| Grant | Dec 1, 2020 | ||||
| Strategic | Nov 6, 2019 | ||||
| Grant | Apr 13, 2018 | ||||
Debt | Mar 28, 2018 |
Key People
Founding team and executive leadership
Vyriad Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Mirae Asset | Series B |
| NIH RADx | Grant |
| Mayo Clinic Ventures | Series B |
| Rochester Area Economic Development, Inc. | Grant, Debt, Series B |
| Southeast Minnesota Capital Partners | Grant, Series B |
| Mirae Asset Venture Investment | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 23, 2025
$25M round led by Harry H. Stine and Stine Seed Company.
- Dec 16, 2025
Presented at the ASH 2025 conference.
Vyriad Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Vyriad's valuation, stock price, and market status.